Clinical Trials

ALT – 110
Currently enrolling : Phase 1

The world’s first drug that targets an alternative splice form ALT-110, the first of Alteris’ products, currently is being tested in a Phase I clinical trial partially supported by the RAID (“Rapid Access Investigational Drug”) program of the National Cancer Institute, National Institutes of Health. The production of ALT-110 under GMP conditions is being carried out by a company which has extensive experience in this area, American Peptide. They are a certified facility and can provide all necessary documentation to the FDA for this drug. The Phase I trial is being carried out at the University of Washington, School of Medicine through a collaboration with scientific and clinical investigators with extensive experience in the design and completion of human vaccine trials in cancer patients.

Clinical trial information on ALT-110, the world’s first drug that targets a tumor specific splice variant.

• Phase I study to monitor safety as well as immunologic and clinical parameters
  
• Trial conducted at the University of Washington, Seattle, SWOG protocol 0114
  
• Patients with tumors expressing EGFRvIII and meeting other eligibility criteria will be enrolled
  
• Patients are vaccinated with EGFRvIII peptide in combination with GM-CSF for up to six 28 d cycles
  
• First 5 patients injected without significant side effects
  
• Evidence of immunity in 3 patients (both antibody and T cell)

http://www.clinicaltrials.gov

http://www.swog.org/visitors